Navigation Links
Blame the environment: Why vaccines may be ineffective for some people
Date:12/1/2010

A new discovery may explain why a tuberculosis vaccine is not as effective for some people as anticipated, and potentially explains why other vaccines do not work as well for some as they do for others. In a research report presented in the December 2010 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org), scientists from Singapore show that Mycobacterium chelonae, a common environmental bacterium found in soil and water, can decrease the effectiveness of the bacille Calmette-Guerin (BCG) vaccine used to prevent tuberculosis, especially in countries outside of the United States.

"Uncovering the reasons why BCG is failing will help researchers in designing new, more effective vaccines against TB," said Geok Teng Seah, Ph.D., a researcher involved in the work from the Department of Microbiology at the National University of Singapore. "This will give us more tools to fight this globally significant infectious disease."

To make this discovery, scientists studied mice with and without prior exposure to M. chelonae. When subsequently given BCG vaccine, the mice with prior exposure to M. chelonae produced higher amounts of suppressive chemical signals; these chemical signals are believed to reduce the level of immunity induced by BCG vaccine in the host mice. Then the researchers extracted certain white blood cells with known suppressive functions from both exposed and unexposed mice. After transferring these cells into separate groups of unexposed mice, they found that recipients of suppressor cells from M. chelonae exposed mice did not respond as strongly to BCG vaccine as recipients of suppressor cells from unexposed donor mice. This indicates that the suppressor cells from M. chelonae exposed mice are functionally different from those of unexposed mice. Ultimately, the data suggest that these suppressor cells, induced in the host when exposed to M. chelonae, dampen the effectiveness of the BCG vaccine.

"This study sheds important light on why many immunological therapies and vaccines look great in the lab, but fall short in the real world," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "Humans are exposed to many more non-disease causing bacteria and viruses compared to relatively clean laboratory animals, and as this study shows with a TB vaccine, environmental exposure to one kind of bacteria can influence the efficacy of immunity to different, more dangerous bugs."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Lacking Finance Education to Blame for Rising Insolvency?
2. Dont blame cities for climate change, see them as solutions
3. Discovery in legumes could reduce fertilizer use, aid environment: Stanford researchers
4. Cow vaccines go vroom
5. Scientists use computer algorithms to develop seasonal flu vaccines
6. New bacterial signaling molecule could lead to improved vaccines
7. Prescription drug could boost effects of vaccines for HIV and other diseases
8. Vaccines preventing pneumococcal disease protect African children with sickle-cell disease
9. GEN reports on the promise of DNA vaccines
10. Major breakthrough may pave the way for therapeutic vaccines
11. Bug barcode readers hold out promise of universal vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... shareholders, Clean Technology Fund I, LP and Clean Technology ... based venture capital funds which together hold approximately 59% ... diluted, as converted basis), that they have entered into ... holdings in Biorem to TUS Holdings Co. Ltd. ("TUS") ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology: